3-Heptylmethylamine | 63834-43-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 3-Heptylmethylamine
• 英文别名: N-methylheptan-3-amine
• CAS: 63834-43-5
• 化学式: C₈H₁₉N
• 分子量: 129.24
• InChiKey: RQVCGLLQEIIZIL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  9
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• Nucleic-acid triggered release of molecules
  申请人：Riken

  公开号：EP2105146A1

  公开（公告）日：2009-09-30

  It is an object of the present invention to provide a method for highly selectively releasing a molecule of interest such as an agent at a desired site while suppressing the influence of catabolic enzymes existing in vivo. The present invention provides a method for releasing a molecule of interest, which comprises steps of: hybridizing each of an "electron donor-first nucleic acid probe" molecule formed by binding an electron donor structure to a first nucleic acid probe having a nucleotide sequence complementary to a portion of a target nucleic acid sequence and a "molecule of interest-electron acceptor-second nucleic acid probe" molecule formed by binding an electron acceptor structure having a molecule of interest and an azide group to a second nucleic acid probe that has a nucleotide sequence complementary to said target nucleic acid sequence and differing from that of said first nucleic acid probe, to said target nucleic acid sequence; and allowing said "electron donor-first nucleic acid probe" molecule to act on said "molecule of interest-electron acceptor-second nucleic acid probe" molecule, so as to release said molecule of interest.

  本发明的目的是提供一种高度选择性地在所需位置释放感兴趣的分子（如药物），同时抑制体内存在的分解酶的影响的方法。本发明提供了一种释放感兴趣分子的方法，包括以下步骤：将电子给体结构与具有与目标核酸序列部分互补的第一核酸探针结合形成的“电子给体-第一核酸探针”分子和将具有感兴趣分子和叠氮基团的电子受体结构与具有与目标核酸序列互补且与第一核酸探针不同的第二核酸探针结合形成的“感兴趣分子-电子受体-第二核酸探针”分子与目标核酸序列杂交；并使“电子给体-第一核酸探针”分子作用于“感兴趣分子-电子受体-第二核酸探针”分子，以释放所述感兴趣分子。
• 5-Substituted-2-Arylpyridines
  申请人：Ge Ping

  公开号：US20080107608A1

  公开（公告）日：2008-05-08

  Novel 5-substituted-2-arylpyridine compounds are provided. Such compounds can act as selective modulators of CRP receptors. The 5-substituted-2-arylpyridine compounds provided herein are useful in the treatment of a number of CNS and periphereal disorders, particularly stress, anxiety, depression, cardiovascular disorders, and eating disorders. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also provided. Compounds provided are also useful as probes for the localization of CRF receptors and as standards in assays for CRF receptor binding. Methods of using the compounds in receptor localization studies are given.

  本发明提供了一种新型的5-取代-2-芳基吡啶化合物。这些化合物可以作为选择性调节CRP受体的调节剂。本发明提供的5-取代-2-芳基吡啶化合物在治疗许多中枢神经系统和周围疾病方面具有用途，特别是在应对压力、焦虑、抑郁、心血管疾病和进食障碍方面。本发明还提供了治疗这些疾病的方法以及配制的药物组合物。提供的化合物还可用作CRF受体定位的探针，以及CRF受体结合测定中的标准物质。给出了使用这些化合物进行受体定位研究的方法。
• INHIBITORS OF BRUTON'S TYROSINE KINASE
  申请人：PHARMACYCLICS, INC.

  公开号：US20140057907A1

  公开（公告）日：2014-02-27

  Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate irreversible inhibitor of a protein, including a kinase.

  本文介绍了不可逆激酶抑制剂化合物，合成这种不可逆抑制剂的方法，以及使用这种不可逆抑制剂治疗疾病的方法。此外，本文还介绍了确定蛋白质，包括激酶的适当不可逆抑制剂的方法、测定和系统。
• BTK INHIBITORS FOR THE TREATMENT OF CNS MALIGNANCIES
  申请人：Pharmacyclics LLC

  公开号：US20160008366A1

  公开（公告）日：2016-01-14

  Described herein are irreversible Btk inhibitor compounds, and methods for using such irreversible inhibitors in the treatment of CNS malignancies.

  本文描述了不可逆的Btk抑制剂化合物，以及使用这些不可逆抑制剂治疗中枢神经系统恶性肿瘤的方法。
• FORMULATIONS CONTAINING REVERSIBLE COVALENT COMPOUNDS
  申请人：PRINCIPIA BIOPHARMA INC.

  公开号：US20160045503A1

  公开（公告）日：2016-02-18

  Oral pharmaceutical formulations comprising reversible covalent compounds having a Michael acceptor moiety, a process of their production and use of these formulations for the treatment of diseases treatable by such compounds such as cancer and autoimmune diseases.

  口服药物制剂包括具有Michael受体基团的可逆共价化合物，其生产过程以及利用这些制剂治疗可通过此类化合物治疗的疾病，例如癌症和自身免疫性疾病。